MedPath

Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI)

Phase 4
Conditions
patients for indicated antiplatelet treatment after percutaneous coronary intervention(PCI)
Registration Number
JPRN-UMIN000001610
Lead Sponsor
Graduate School of Medicine Science, Kumamoto University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
240
Inclusion Criteria

Not provided

Exclusion Criteria

Patients were excluded if patients had been malignant disease, previous upper abdominal surgery, neuropsychiatric disorder, organic brain damage, severe hepato-renal disorder, symptoms suggesting or were pregnant.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The current study attempted to compare the efficacy of rabeprazole with omeprazole in patients indicated for antiplatelet treatment after PCI
Secondary Outcome Measures
NameTimeMethod
upper gastrointestinal bleeding. Gastrointestinal symptom(Gastrointesitinal Symptom Rating Scale).
© Copyright 2025. All Rights Reserved by MedPath